Table 3.

Cohort characteristics of management studies

Study, year	Total No of cases	Total venous thromboembolism events (%)	Mean age (years)	Male sex (%)	d-dimer test*	Cut-off value	Reference standard	Laboratory technician blinded†	Radiologist blinded‡	Clinical probability tool§	Total No of cases lost to follow up	Cases with prior deep vein thrombosis included
Bates et al, 2003102	556	56 (10.1)	62	38	MDA	0.5 μg fibrin equivalent units/ml	Venous ultrasound	Yes	Unknown	Wells	0	No
Schutgens et al, 2003104	812	317 (39.0)	Unknown	Unknown	Tinaquant	500 μg fibrin equivalent units/l	Venous ultrasound	Unknown	Unknown	Wells	15	No
Kearon et al, 2001103	445	64 (14.4)	60	36	SimpliRED	Any agglutination	Venous ultrasound, impedance plethysmography, venography	Unknown	Unknown	Wells	Unknown	No
Perrier et al, 199913	474	120 (25.3)	61	38	VIDAS	500 μg/l	Venous ultrasound, phlebography	Unknown	Yes	Implicit	4	Unknown
Tick et al, 2000105	811	350 (43.2)	62	36	SimpliRED	Any agglutination	Venous ultrasound	Yes	Unknown	Wells	0	Unknown
Aguilar et al, 2002106	134	26 (19.4)	71	48	STA-LIA	0.4 μg/ml	Venous ultrasound	Unknown	Yes	Wells	Unknown	Unknown

^*MDA d-dimer assay (Organon Teknika, now bio-Mérieux, Durham, North (Carolina); Tinaquant (Roche, Germany); SimpliRED (Agen Biomedical, Brisbane, Australia); VIDAS (bio-Mérieux, Durham, North Carolina); STA-LIA (Diagnostica Stago, Asniéres sur Seine, France).

^†Blinded to patient's clinical probability score and radiology result.

^‡Blinded to patient's clinical probability score and d-dimer result.

^§Wells et al. 1995²; Wells et al 1997¹².